Evidence map›Paper›PMID 40883730›Full record

SynthesisBMC urology2025

Stem cell therapy for erectile dysfunction: promise or reality? - a systematic review and meta-analysis of clinical trials.

Samet Senel, Ahmet Halil Sevinc, Huseyin Gultekin, Abduvaliyev Jaxongir Ravshanbekovich, Huseyin Besiroglu, Murat Dursun, Ates Kadioglu

Abstract readSystematic ReviewMeta-Analysis
In one paragraph

Synthesis in BMC urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Samet SenelIstanbul Faculty of Medicine, Department of Urology, Section of Andrology, Istanbul, Türkiye.
Ahmet Halil SevincIstanbul Faculty of Medicine, Department of Urology, Section of Andrology, Istanbul, Türkiye.
Huseyin GultekinDepartment of Urology, Ankara City Hospital, Ankara, Türkiye.
Abduvaliyev Jaxongir RavshanbekovichDepartment of Urology, National Medical Centre, Tashkent, Uzbekistan.
Huseyin BesirogluDepartment of Urology, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Türkiye.
Murat DursunIstanbul Faculty of Medicine, Department of Urology, Section of Andrology, Istanbul, Türkiye.
Ates KadiogluIstanbul Faculty of Medicine, Department of Urology, Section of Andrology, Istanbul, Türkiye. itfabd@istanbul.edu.tr.ORCID http://orcid.org/0000-0002-4239-7638

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe outcomes of clinical trials on stem cell therapy (SCT) on erectile dysfunction (ED) treatment are promising but there is still no conclusive evidence regarding its efficacy. The aim of this meta-analysis is to compile studies that assess the effectiveness of SCT on ED to reach a more reliable conclusion.

methodsThe meta-analysis was registered to PROSPERO (CRD42024540511). We utilized the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guideline to report the outcomes. Articles published from January 2000 to May 2024 were included for systematic review. We performed a systematic search using keywords: "stem cell" AND ("erectile dysfunction" OR "erectile function" OR "erection" OR "impotence").

resultsWe initially identified 2,013 studies in full publications or abstracts using the search terms. Eleven studies were included in systematic review and six of them were included in meta-analysis. Most studies included in systematic review reported improvements in erectile function following intracavernosal SCT. The meta-analysis revealed significant improvements at six months in international index of erectile function-5 (IIEF-5), international index of erectile function-erectile function domain) IIEF-EF, erectile hardness score (EHS), and peak systolic velocity (PSV) (p < 0.05). End-diastolic velocity (EDV) increased significantly at 3 months (p = 0.031) but not at six months (p = 0.868). Heterogeneity ranged from low to high (I² = 0-71.2%). No significant publication bias was detected (Egger's test p > 0.05).

conclusionIntracavernosal SCT may increase scores on the questionnaires evaluated compared to baseline at six months which currently represent the longest reported follow-up duration but comparative trials with longer follow-up periods are needed to draw more definitive conclusions and reveal long-term effect.

Indexed as

Erectile DysfunctionStem Cell TransplantationClinical Trials as TopicHumansMaleTreatment OutcomeEDErectile dysfunctionRegenerative therapyStem cell

Identifiers

PMID40883730
PMCPMC12395856

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.